|Bid||39.46 x 900|
|Ask||39.50 x 1100|
|Day's Range||38.76 - 40.30|
|52 Week Range||20.15 - 99.95|
|Beta (5Y Monthly)||2.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021 - May 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.57|
A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.
In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the difference between ex vivo gene editing (outside the body) and in vivo editing (within the patient). CRISPR Therapeutics (NASDAQ: CRSP) and its partner Vertex Pharmaceuticals (NASDAQ: VRTX) have mastered ex vivo gene editing, but the strategy is limited to diseases where cells can be manipulated outside the body. Up-and-coming gene editing companies may have a bigger opportunity if they can master the in vivo technique.
You've no doubt heard the investing adage to "buy the dip." But what if the dip is a really bad one? Sometimes buying stocks that fall significantly isn't such a great idea. On the other hand, there are other cases where scooping up shares when they've retreated a lot can pay off in a big way over the long run.